BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19573982)

  • 1. Antitumor activity and pharmacokinetic properties of ARS-interacting multi-functional protein 1 (AIMP1/p43).
    Han JM; Myung H; Kim S
    Cancer Lett; 2010 Jan; 287(2):157-64. PubMed ID: 19573982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The activity of aminoacyl-tRNA synthetase-interacting multi-functional protein 1 (AIMP1) on endothelial cells is mediated by the assembly of a cytoskeletal protein complex.
    Jackson VC; Dewilde S; Albo AG; Lis K; Corpillo D; Canepa B
    J Cell Biochem; 2011 Jul; 112(7):1857-68. PubMed ID: 21416500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene transfer of AIMP1 and B7.1 into epitope-loaded, fibroblasts induces tumor-specific CTL immunity, and prolongs the survival period of tumor-bearing mice.
    Kim TS; Lee BC; Kim E; Cho D; Cohen EP
    Vaccine; 2008 Nov; 26(47):5928-34. PubMed ID: 18793691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human interleukin-24 suppresses gastric carcinoma cell growth in vitro and in vivo.
    Yan S; Zhang H; Xie Y; Sheng W; Xiang J; Ye Z; Chen W; Yang J
    Cancer Invest; 2010 Jan; 28(1):85-93. PubMed ID: 19916746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.
    Baker DP; Lin EY; Lin K; Pellegrini M; Petter RC; Chen LL; Arduini RM; Brickelmaier M; Wen D; Hess DM; Chen L; Grant D; Whitty A; Gill A; Lindner DJ; Pepinsky RB
    Bioconjug Chem; 2006; 17(1):179-88. PubMed ID: 16417267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural separation of different extracellular activities in aminoacyl-tRNA synthetase-interacting multi-functional protein, p43/AIMP1.
    Han JM; Park SG; Lee Y; Kim S
    Biochem Biophys Res Commun; 2006 Mar; 342(1):113-8. PubMed ID: 16472771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effect of endothelial monocyte-activating polypeptide-II on human prostate adenocarcinoma in mouse xenograft model.
    Reznikov AG; Chaykovskaya LV; Polyakova LI; Kornelyuk AI
    Exp Oncol; 2007 Dec; 29(4):267-71. PubMed ID: 18199981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of CPUY013, a novel Topo I inhibitor, on human gastric adenocarcinoma BGC823 cells in vitro and in vivo].
    Ji YB; Zhou JH; Zuo MX; You QD
    Yao Xue Xue Bao; 2008 Aug; 43(8):811-8. PubMed ID: 18956773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tyroservatide inhibits the growth of human hepatocarcinoma in nude mice].
    Jia J; Lu R; Fu Z; Qiu S; Shi LX; Jian X; Liu JY; Li HQ; Che XC; Yao Z
    Zhonghua Zhong Liu Za Zhi; 2006 Jun; 28(6):426-8. PubMed ID: 17152487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor effects of polybutylcyanoacrylate nanoparticles of diallyl trisulfide on orthotopic transplantation tumor model of hepatocellular carcinoma in BALB/c nude mice.
    Zhang ZM; Yang XY; Deng SH; Xu W; Gao HQ
    Chin Med J (Engl); 2007 Aug; 120(15):1336-42. PubMed ID: 17711740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
    O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Construction of autocatalytic caspase-3 driven by amplified human telomerase reverse transcriptase promoter and its enhanced efficacy of inducing apoptosis in human ovarian carcinoma].
    Song Y; Shen K; He CX
    Zhonghua Fu Chan Ke Za Zhi; 2007 Sep; 42(9):617-22. PubMed ID: 17983518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions.
    Choo EF; Belvin M; Boggs J; Deng Y; Hoeflich KP; Ly J; Merchant M; Orr C; Plise E; Robarge K; Martini JF; Kassees R; Aoyama RG; Ramaiya A; Johnston SH
    Drug Metab Dispos; 2012 May; 40(5):919-27. PubMed ID: 22315332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
    Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
    Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
    Song Y; Shen K; Yu JR
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
    Bell SJ; Fam CM; Chlipala EA; Carlson SJ; Lee JI; Rosendahl MS; Doherty DH; Cox GN
    Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of the novel human cytokine AIMP1 in an in vivo tumor model.
    Lee YS; Han JM; Kang T; Park YI; Kim HM; Kim S
    Mol Cells; 2006 Apr; 21(2):213-7. PubMed ID: 16682815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.